{"id":439121,"date":"2010-03-17T13:14:51","date_gmt":"2010-03-17T17:14:51","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=68975"},"modified":"2010-03-17T13:14:51","modified_gmt":"2010-03-17T17:14:51","slug":"acucela-gets-fda-fast-track","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/439121","title":{"rendered":"Acucela Gets FDA Fast Track"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/macular-degeneration\/\">Macular Degeneration<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/Drugs\/\">Drugs<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Acucela and its partner, Japan-based Otsuka Pharmaceutical, <a href=\"http:\/\/www.businesswire.com\/portal\/site\/home\/permalink\/?ndmViewId=news_view&amp;newsId=20100317005506&amp;newsLang=en\">said today<\/a> they have received &#8220;Fast Track&#8221; designation for an application to market a new drug for the &#8220;dry&#8221; form of age-related macular degeneration. The designation means that the companies will\u00a0 be able to file data on their drug,\u00a0 ACU-4429, as it becomes available, and which makes it possible for the companies to get a faster-than-usual six-month review that is sometimes given to applications to treat serious or life-threatening conditions.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/03\/17\/acucela-gets-fda-fast-track\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Acucela%20Gets%20FDA%20Fast%20Track%20http:\/\/xconomy.com\/?p=68975\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/03\/17\/acucela-gets-fda-fast-track\/&#038;t=Acucela%20Gets%20FDA%20Fast%20Track\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/03\/17\/acucela-gets-fda-fast-track\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Acucela+Gets+FDA+Fast+Track&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F03%2F17%2Facucela-gets-fda-fast-track%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\t     \t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=799cf66a86354f751ef403504745152e&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=799cf66a86354f751ef403504745152e&#038;p=1\"\/><\/a><br \/>\n<!-- foo --><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/2Zbtj6dqdqJ1wn-wuEV1kIFMGe4\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/2Zbtj6dqdqJ1wn-wuEV1kIFMGe4\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/2Zbtj6dqdqJ1wn-wuEV1kIFMGe4\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/2Zbtj6dqdqJ1wn-wuEV1kIFMGe4\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/fmEdycu1_ZM\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Macular Degeneration, Drugs Luke Timmerman wrote: Acucela and its partner, Japan-based Otsuka Pharmaceutical, said today they have received &#8220;Fast Track&#8221; designation for an application to market a new drug for the &#8220;dry&#8221; form of age-related macular degeneration. The designation means that the companies will\u00a0 be able to file data on their drug,\u00a0 ACU-4429, as [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-439121","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/439121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=439121"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/439121\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=439121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=439121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=439121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}